Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.   

RSS icon

Clopidogrel vs. aspirin: Tracking the chronic maintenance period after PCI for different risk groups

As more high-risk patients undergo PCI, what is the best antiplatelet strategy following an initial event-free period of DAPT? Does it change after complex PCI? Researchers aimed to answer these questions, and many others, with new findings published in JAMA Cardiology.

FDA approves new short-term treatment for AFib, atrial flutter in critical care settings

Landiolol, sold by AOP Health under the brand name Rapiblyk, is an intravenous treatment designed to start working right away.

pharmaceutical drug approval process

FDA approves acoramidis, BridgeBio’s new ATTR-CM drug

Acoramidis, a selective transthyretin stabilizer being sold under the brand name Attruby, is now the second ATTR-CM medication to gain FDA approval.

Medtronic has received U.S. Food and Drug Administration (FDA) clearance for its new InPen smartphone app and announced the launch of its new Smart MDI system. Smart MDI was designed to provide real-time insights for users on multiple daily injection (MDI) therapy. It includes the InPen smart insulin pen, the InPen app and Medtronic’s disposable, all-in-one Simplera continuous glucose monitor (CGM), which received U.S. Food and Drug Administration approval back in August.

Medtronic receives key FDA clearance, launches new diabetes system

Medtronic designed its new Smart MDI system to provide real-time insights to users on multiple daily injection therapy.

Daniel Judge, MD, director of the cardiovascular genetics program, Medical University of South Carolina, the Edwin W. and Teresa H. Rogers Endowed Chair for Cardiovascular Research, Medical University of South Carolina, presented the results of the late-breaking ATTRibute-CM study for the drug acoramidis used to treat transthyretin amyloidosis at AHA 2024.

ATTR-CM drug acoramidis, now approved by the FDA, linked to positive long-term data

Cardiovascular Business spoke with cardiologist Daniel Judge, MD, about the long-term benefits of acoramidis, a new drug therapy that just received FDA approval to treat transthyretin amyloid cardiomyopathy.

Video of Martha Gulati explaining preventive cardiology advanacements for obese patients. #AHA24 #AHA2024 #CVprev

Martha Gulati highlights 'exciting' progress in preventive cardiology

Martha Gulati, MD, spoke to Cardiovascular Business at AHA Scientific Sessions 2024 about key developments in obesity treatment and CVD prevention.

Deepak Bhatt, MD, MPH, MBA, director of the Mount Sinai Fuster Heart Hospital, explains the research and therapies in development to treat coronary inflammation. In 2023, the FDA cleared the use colchicine and since there has been an explosion of interest in this area. #TCT #TCT24 #TCT2024 #AHA24

Cardiologist examines the latest breakthroughs in coronary inflammation research

Deepak Bhatt, MD, MPH, MBA, spoke to Cardiovascular Business about the growing importance of evaluating coronary inflammation in heart patients. There has been an explosion of interest in this area since the FDA's 2023 clearance of colchicine.

Immediate Past President of the American College of Cardiology (ACC) Hadley Wilson, MD, FACC, executive vice chair of Atrium Health Sanger Heart and Vascular Institute and a clinical professor of medicine at Wake Forest University School of Medicine, details the top late-breaking studies at AHA 2024. #AHA24 #AHA2024

9 key takeaways from AHA 2024 in Chicago

Hadley Wilson, MD, spoke to Cardiovascular Business at the three-day event to discuss key late-breaking studies and trends. Topics included new drug treatments, AI and much more.

Displaying 1 - 8 of 295

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.